ALLR Stock Overview
A clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Allarity Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.64 |
52 Week High | US$283.20 |
52 Week Low | US$0.63 |
Beta | 0.52 |
1 Month Change | -54.03% |
3 Month Change | -92.07% |
1 Year Change | -99.73% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
ALLR | US Biotechs | US Market | |
---|---|---|---|
7D | -19.2% | 3.2% | 1.7% |
1Y | -99.7% | 6.2% | 26.3% |
Return vs Industry: ALLR underperformed the US Biotechs industry which returned 6% over the past year.
Return vs Market: ALLR underperformed the US Market which returned 26.3% over the past year.
Price Volatility
ALLR volatility | |
---|---|
ALLR Average Weekly Movement | 16.0% |
Biotechs Industry Average Movement | 11.1% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ALLR's share price has been volatile over the past 3 months.
Volatility Over Time: ALLR's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 6 | Thomas Jensen | www.allarity.com |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty.
Allarity Therapeutics, Inc. Fundamentals Summary
ALLR fundamental statistics | |
---|---|
Market cap | US$197.42k |
Earnings (TTM) | -US$20.94m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ALLR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALLR income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$20.94m |
Earnings | -US$20.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -67.78 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -41.6% |
How did ALLR perform over the long term?
See historical performance and comparison